4044-99-9

Basic information

• Product Name: 6-BROMO-2-METHYLIMIDAZO[1,2-A]PYRIDINE
• Synonyms: 6-BROMO-2-METHYLIMIDAZO[1,2-A]PYRIDINE;IMidazo[1,2-a]pyridine, 6-broMo-2-Methyl-
• CAS NO: 4044-99-9
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.07
• Product Categories: Fused Ring Systems;Halides
• Mol File: 4044-99-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 101.0-101.5 °C
• Appearance: /
• Density: 1.6 g/cm³
• Refractive Index: 1.663
• PKA: 5.47±0.10(Predicted)
• CAS DataBase Reference: 6-BROMO-2-METHYLIMIDAZO[1,2-A]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-METHYLIMIDAZO[1,2-A]PYRIDINE(4044-99-9)
• EPA Substance Registry System: 6-BROMO-2-METHYLIMIDAZO[1,2-A]PYRIDINE(4044-99-9)

Safety Data

• Hazardous Substances Data: 4044-99-9(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-methylimidazo[1,2-a]pyridine is a chemical compound with the molecular formula C7H6BrN3. It is a brominated derivative of imidazo[1,2-a]pyridine, which is a bioactive heterocyclic compound. This chemical is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has also been found to exhibit mutagenic properties in certain studies, making it a potential carcinogen. Its structure and properties make it a valuable tool for studying the biological effects and mechanisms of action of similar compounds.

InChI:InChI=1/C8H7BrN2/c1-6-4-11-5-7(9)2-3-8(11)10-6/h2-5H,1H3

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 598-31-2 1-bromoacetone 
• 78-95-5 chloroacetone 

Downstream Products

• 1246184-50-8 6-bromo-3-iodo-2-methylimidazo[1,2-a]pyridine 
• 728864-58-2 6-bromo-2-methylimidazo [1,2-a]pyridine-3-carbaldehyde 

Relevant articles and documents

Identification of the Privileged Position in the Imidazo[1,2-a]pyridine Ring of Phosphonocarboxylates for Development of Rab Geranylgeranyl Transferase (RGGT) Inhibitors

Members of the Rab GTPase family are master regulators of vesicle trafficking. When disregulated, they are associated with a number of pathological states. The inhibition of RGGT, an enzyme responsible for post-translational geranylgeranylation of Rab GTPases represents one way to control the activity of these proteins. Because the number of molecules modulating RGGT is limited, we combined molecular modeling with biological assays to ascertain how modifications of phosphonocarboxylates, the first reported RGGT inhibitors, rationally improve understanding of their structure-activity relationship. We have identified the privileged position in the core scaffold of the imidazo[1,2-a]pyridine ring, which can be modified without compromising compounds' potency. Thus modified compounds are micromolar inhibitors of Rab11A prenylation, simultaneously being inactive against Rap1A/Rap1B modification, with the ability to inhibit proliferation of the HeLa cancer cell line. These findings were rationalized by molecular docking, which recognized interaction of phosphonic and carboxylic groups as decisive in phosphonocarboxylate localization in the RGGT binding site.

TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted 5,6,7,8-tetrahydroimidazo[l,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory di

FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted benzimidazole, imidazo[1,2-α]pyridine and pyrazolo[1,5- α]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human a